Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Other Non Operating Income (2016 - 2025)

Historic Other Non Operating Income for Catalyst Pharmaceuticals (CPRX) over the last 14 years, with Q3 2025 value amounting to $4.8 million.

  • Catalyst Pharmaceuticals' Other Non Operating Income fell 2426.94% to $4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.0 million, marking a year-over-year increase of 8237.04%. This contributed to the annual value of $21.1 million for FY2024, which is 17456.81% up from last year.
  • According to the latest figures from Q3 2025, Catalyst Pharmaceuticals' Other Non Operating Income is $4.8 million, which was down 2426.94% from $3.0 million recorded in Q2 2025.
  • Catalyst Pharmaceuticals' 5-year Other Non Operating Income high stood at $11.3 million for Q4 2024, and its period low was -$833000.0 during Q3 2023.
  • Over the past 5 years, Catalyst Pharmaceuticals' median Other Non Operating Income value was $1.7 million (recorded in 2023), while the average stood at $2.5 million.
  • The largest annual percentage gain for Catalyst Pharmaceuticals' Other Non Operating Income in the last 5 years was 300845.07% (2022), contrasted with its biggest fall of 62258.06% (2022).
  • Quarter analysis of 5 years shows Catalyst Pharmaceuticals' Other Non Operating Income stood at $71000.0 in 2021, then skyrocketed by 3008.45% to $2.2 million in 2022, then skyrocketed by 127.23% to $5.0 million in 2023, then soared by 126.08% to $11.3 million in 2024, then plummeted by 57.95% to $4.8 million in 2025.
  • Its last three reported values are $4.8 million in Q3 2025, $3.0 million for Q2 2025, and $7.9 million during Q1 2025.